Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07768306 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07768306 · ClinicalTrials.gov record · last posted 2026-08-17

Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM

Name: Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM — clinical trial record (NCT07768306)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorNorroy Bioscience Co., LTD

Started2026-09

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

68Ga-NYM096 is a carbonic anhydrase IX (CAIX)-targeted imaging agent that is under clinical development as a non-invasive diagnostic imaging agent for the detection of clear cell renal cell carcinoma (ccRCC). The Phase 1 study is to evaluate the safety, pharmacokinetics, radioactivity distribution, radiation safety and preliminary diagnostic performance in participants with indeterminate renal masses (IRM)

Trial Details

NCT Number	NCT07768306
Lead Sponsor	Norroy Bioscience Co., LTD
Conditions	Clear Cell Renal Cell Carcinoma (ccRCC)
Enrollment	20 participants
Start Date	2026-09
Primary Completion	2027-03 (estimated)
Study Completion	2027-04 (estimated)
Updated on ClinicalTrials.gov	2026-08-17